Back to top
more

STAAR Surgical (STAA)

(Delayed Data from NSDQ)

$46.65 USD

46.65
724,494

+0.67 (1.46%)

Updated May 7, 2024 04:00 PM ET

After-Market: $45.25 -1.40 (-3.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (164 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

STAAR Surgical (STAA) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Strong growth in EVO ICL units led by increased market adoption is likely to have driven STAAR Surgical's (STAA) Q4 revenues.

STAAR Surgical Company (STAA) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Staar Surgical (STAA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Cardinal Health (CAH) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of 16.81% and 2.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AmerisourceBergen (ABC) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

AmerisourceBergen (ABC) delivered earnings and revenue surprises of 3.44% and 0.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Staar Surgical (STAA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Staar Surgical (STAA) closed the most recent trading day at $69.42, moving +0.78% from the previous trading session.

Staar Surgical (STAA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Staar Surgical (STAA) closed at $73.93, marking a +1.97% move from the previous day.

Why You Should Hold Elevance Health (ELV) in Your Portfolio

by Zacks Equity Research

Elevance Health (ELV) remains well-poised for growth due to a growing customer base within its Government and IngenioRx businesses coupled with solid cash-generating abilities.

Teladoc (TDOC) Unveils App to Simplify Whole-Person Care

by Zacks Equity Research

Teladoc Health (TDOC) launches a digital app that will provide a broad range of TDOC's services to cater to the whole-person health needs of members.

Here's Why You Should Hold Cigna (CI) Stock in Your Portfolio

by Zacks Equity Research

Cigna (CI) remains well-poised for growth on the back of the solid Evernorth and Cigna Healthcare businesses, an expanding customer base and robust cash-generating abilities.

Community Health (CYH) Sells Hospital, Renews Health Net Tie-Up

by Zacks Equity Research

Community Health (CYH) announces the divestiture of its West Virginia hospital and the expansion of its alliance with Health Net, thereby undertaking initiatives to boost business prospects.

New Strong Buy Stocks for January 4th

by Zacks Equity Research

STAA, CASY, THRM, MP and UTHR have been added to the Zacks Rank #1 (Strong Buy) List on January 4 , 2023.

Is the Options Market Predicting a Spike in STAAR Surgical (STAA) Stock?

by Zacks Equity Research

Investors need to pay close attention to STAAR Surgical (STAA) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in STAAR (STAA) Stock?

by Zacks Equity Research

Investors need to pay close attention to STAAR (STAA) stock based on the movements in the options market lately.

Staar Surgical (STAA) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Staar Surgical (STAA) delivered earnings and revenue surprises of 76.19% and 1.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

LabCorp (LH) delivered earnings and revenue surprises of -0.64% and 5.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 Reasons Why Growth Investors Shouldn't Overlook Staar Surgical (STAA)

by Zacks Equity Research

Staar Surgical (STAA) possesses solid growth attributes, which could help it handily outperform the market.

Is Staar Surgical (STAA) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.

Staar Surgical (STAA) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Staar Surgical (STAA)

by Zacks Equity Research

Staar Surgical (STAA) possesses solid growth attributes, which could help it handily outperform the market.

What Makes Staar Surgical (STAA) a New Buy Stock

by Zacks Equity Research

Staar Surgical (STAA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Glaukos (GKOS) Strong Portfolio Driving Sales Amid Competition

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.

Staar Surgical (STAA) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Staar Surgical (STAA) delivered earnings and revenue surprises of 68% and 1.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SmileDirectClub (SDC) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

SmileDirectClub (SDC) delivered earnings and revenue surprises of -21.43% and 13.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Beats Q2 Earnings Estimates

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of 3.57% and 2.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Here is Why Growth Investors Should Buy Staar Surgical (STAA) Now

by Zacks Equity Research

Staar Surgical (STAA) is well positioned to outperform the market, as it exhibits above-average growth in financials.